Want to see STVN full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.15Last Year’s EPS
0.13Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted strong top-line growth, robust Biopharmaceutical & Diagnostic Solutions momentum (notably syringes, biologics and GLP1 exposure), expanding high-value solution mix, margin expansion on an adjusted basis, and clear progress on strategic capacity investments. Offsetting these positives were a sharp revenue decline in the Engineering segment, segment-level gross margin compression for BDS driven by ramp-related depreciation, FX and tariff headwinds, a higher tax rate, modest free cash flow in the quarter due to heavy growth capex, and slower order conversion cycles in Engineering. Management reiterated full-year guidance and emphasized demand-driven capacity investment and operational optimization.Company Guidance
Top-line Growth
Revenue grew 10% at constant currency and 7% reported to EUR 273.6 million in Q1 FY2026 versus Q1 2025.
BDS Segment Outperformance
Biopharmaceutical and Diagnostic Solutions (BDS) revenue increased 16% at constant currency (13% reported) to EUR 249.0 million, driven by strong demand for pre-fillable syringes and contributions from cartridges and vials.
Syringes and Biologics Momentum
Syringes grew over 20% year-over-year; biologics revenue rose 15% (fastest-growing end market); GLP1s accounted for ~21%–22% of total company revenue in Q1 2026.
Higher Mix of High-Value Solutions
Revenue from high-value solutions increased 17% to EUR 128.6 million and represented 47% of total company revenue (≈52% of BDS segment revenue).
Profitability and Margin Expansion (Adjusted)
Adjusted EBITDA increased 14% to EUR 65.5 million and adjusted EBITDA margin expanded 150 basis points to 23.9%. Adjusted net profit rose 5% to EUR 29.6 million and adjusted diluted EPS increased 10% to EUR 0.11.
Gross and Operating Margin Improvement
Company gross profit margin increased by 30 basis points to 27.5% and operating profit margin rose 70 basis points to 14.2% in Q1 2026.
Operational Progress on Capacity Expansions
Converted an underutilized RTU vial line to a ready-to-use cartridge line (expected commercial production in coming weeks). Latina and Fishers ramps progressing: Fishers device assembly and automation on track (commercial production end-2026/early-2027); RTU 400 EZ-fill cartridge lines targeted for early 2027.
Cash Generation and Investment
Net cash from operating activities was EUR 75.5 million in Q1; capital expenditures totaled EUR 67.6 million ( >90% for growth in Fishers and Latina). Ending cash EUR 111.7 million with maintained guidance for FY2026.
Guidance Reiterated
Company maintained FY2026 guidance: revenue EUR 1.260B–1.290B, adjusted EBITDA EUR 331.8M–346.9M, adjusted diluted EPS EUR 0.59–0.63.
Engineering Segment Margin Recovery Signs
Engineering gross profit margin improved 460 basis points to 15.3% and operating margin improved 190 basis points to 6.6%, reflecting benefits from the optimization plan and right-sizing actions.
STVN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
STVN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $18.93 | $17.96 | -5.11% |
Mar 04, 2026 | $14.68 | $17.44 | +18.81% |
Nov 06, 2025 | $24.91 | $24.32 | -2.36% |
Aug 05, 2025 | $25.49 | $23.01 | -9.73% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Stevanato Group Spa (STVN) report earnings?
Stevanato Group Spa (STVN) is schdueled to report earning on Aug 11, 2026, Before Open (Confirmed).
What is Stevanato Group Spa (STVN) earnings time?
Stevanato Group Spa (STVN) earnings time is at Aug 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is STVN EPS forecast?
STVN EPS forecast for the fiscal quarter 2026 (Q2) is 0.15.